Ovid Therapeutics Inc. Common Stock
OVIDOvid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for rare neurological disorders. Founded to address unmet medical needs, the company specializes in leveraging its expertise in neuroscience to bring innovative therapies to patients with conditions such as rare epilepsies and other central nervous system disorders.
Company News
Ovid Therapeutics stock surged 18% following positive Phase 1 data for OV329, a next-generation GABA-AT inhibitor for epilepsy. The drug showed no treatment-related adverse events at 7mg dose and no ophthalmic changes, addressing safety concerns with existing treatments. The company announced a $60M private placement to fund Phase 2 trials and ex...
Ovid Therapeutics secured $60 million in private investment in public equity (PIPE) financing led by Point72, with participation from multiple hedge funds and asset managers. The company plans to use proceeds to expand development of OV329, a GABA-aminotransferase inhibitor, into tuberous sclerosis complex and infantile spasms indications, along ...
Ovid Therapeutics announced a CEO succession plan with Meg Alexander becoming CEO on January 1, 2026, and Dr. Jeremy M. Levin transitioning to Executive Chair. The company reported positive Phase 1 results for OV329, a next-generation GABA-AT inhibitor, and continues advancing its KCC2 direct activator portfolio.
Ovid Therapeutics, a biopharmaceutical company focused on brain conditions, announced that its President and COO will present at the upcoming TD Cowen conference. The company is advancing a pipeline of novel small molecule candidates for neurological and neuropsychiatric disorders.
The epilepsy market is expected to grow due to an increase in disease prevalence and the launch of emerging therapies. The market is segmented into partial epilepsy, chronic focal epilepsy, and drug-resistant epilepsy, with various treatment options and pipeline drugs.
